GlassScriptPhysician profile
Tao Kim
NPI 1598974214
$7,698.81
in general payments reported to CMS, 2019-2025
28 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $1,039 · 2023: $1,869 · 2024: $1,267 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,443 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,443.22 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $797.74 | 2021-2025 | |
| Abbvie INC. | $779.81 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $759.67 | 2021-2025 | |
| Ucb, INC. | $732.69 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $717.28 | 2021-2025 | Tremfya, Remicade, Stelara |
| Regeneron Healthcare Solutions, INC. | $621.06 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $445.97 | 2022-2025 | |
| Amgen INC. | $375.79 | 2021-2025 | Otezla, Enbrel, Otezla |
| Lilly USA, LLC | $339.94 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $243.64 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $242.56 | 2022-2023 | Sotyktu |
| Organon LLC | $212.04 | 2024-2025 | Vtama, Nexplanon |
| Galderma Laboratories, L.P. | $200.69 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $198.45 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $194.70 | 2021-2025 | Adbry, Spevigo, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $167.93 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Arcutis Biotherapeutics, INC. | $150.62 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.21 | 2023-2024 | Spevigo |
| Kyowa Kirin, INC. | $107.28 | 2021-2024 | Poteligeo |
| Strata Skin Sciences, INC. | $77.50 | 2023 | Xtrac |
| Botanix Sb INC | $40.09 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $37.12 | 2022-2023 | Vtama |
| Iovance Biotherapeutics, INC. | $32.24 | 2025 | Amtagvi |
| Mayne Pharma Commercial LLC | $28.08 | 2022 | |
| Boston Scientific Corporation | $26.38 | 2025 | Wavewriter Alpha Prime 16 |
| Almirall LLC | $15.70 | 2025 | Klisyri |
| Medimetriks Pharmaceuticals, INC. | $14.18 | 2025 | |
| Sebela Pharmaceuticals INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tao Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.